Kennedy Capital Management LLC Makes New $119,000 Investment in Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Kennedy Capital Management LLC purchased a new position in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 25,035 shares of the company’s stock, valued at approximately $119,000. Kennedy Capital Management LLC owned about 0.06% of Prelude Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Acadian Asset Management LLC raised its stake in shares of Prelude Therapeutics by 42.7% in the 1st quarter. Acadian Asset Management LLC now owns 22,110 shares of the company’s stock worth $104,000 after buying an additional 6,615 shares in the last quarter. Vanguard Group Inc. grew its stake in Prelude Therapeutics by 1.0% in the first quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company’s stock valued at $4,821,000 after purchasing an additional 10,143 shares in the last quarter. SG Americas Securities LLC bought a new position in Prelude Therapeutics during the fourth quarter valued at approximately $56,000. Pale Fire Capital SE lifted its stake in shares of Prelude Therapeutics by 106.6% in the 4th quarter. Pale Fire Capital SE now owns 63,581 shares of the company’s stock valued at $271,000 after purchasing an additional 32,800 shares during the last quarter. Finally, Boxer Capital LLC boosted its stake in shares of Prelude Therapeutics by 2.9% during the 4th quarter. Boxer Capital LLC now owns 2,568,287 shares of the company’s stock worth $10,967,000 after acquiring an additional 73,269 shares in the last quarter. Institutional investors and hedge funds own 79.72% of the company’s stock.

Analysts Set New Price Targets

Separately, Barclays downgraded shares of Prelude Therapeutics from an “equal weight” rating to an “underweight” rating and set a $3.00 target price on the stock. in a report on Thursday, June 20th.

Prelude Therapeutics Stock Performance

Shares of PRLD stock opened at $5.65 on Friday. Prelude Therapeutics Incorporated has a 52 week low of $1.66 and a 52 week high of $6.76. The stock’s fifty day moving average is $4.35 and its 200-day moving average is $4.15.

Prelude Therapeutics (NASDAQ:PRLD) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.05. As a group, analysts predict that Prelude Therapeutics Incorporated will post -1.84 earnings per share for the current fiscal year.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.